[144] HCA Healthcare, Inc. SEC Filing
HCA Healthcare, Inc. (HCA) disclosure shows a proposed sale of 3,836 common shares through Merrill Lynch on the New York Stock Exchange with an aggregate market value of $1,606,670.20 and an approximate sale date of 09/08/2025. The shares were acquired on 09/04/2025 via exercises of Stock Appreciation Rights (2,782 and 1,054 shares) and payment was recorded as compensatory.
The filer reports no securities sold in the prior three months and includes the standard representation that the seller is not aware of undisclosed material adverse information. Several identifying fields for the filer and issuer (CIK, names, addresses) are not populated in the provided content.
HCA Healthcare, Inc. (HCA) dichiara una proposta di vendita di 3.836 azioni ordinarie tramite Merrill Lynch alla New York Stock Exchange, per un valore complessivo di mercato di $1.606.670,20 e con data di vendita approssimativa 09/08/2025. Le azioni sono state acquisite il 04/09/2025 tramite l鈥檈sercizio di Stock Appreciation Rights (2.782 e 1.054 azioni) e il pagamento 猫 stato classificato come compensativo.
Il dichiarante segnala che non sono stati venduti titoli nei precedenti tre mesi e include la dichiarazione standard che il venditore non 猫 a conoscenza di informazioni riservate rilevanti non divulgate. Diversi campi identificativi del dichiarante e dell鈥檈mittente (CIK, nomi, indirizzi) non risultano compilati nel contenuto fornito.
HCA Healthcare, Inc. (HCA) informa sobre una propuesta de venta de 3.836 acciones ordinarias a trav茅s de Merrill Lynch en la Bolsa de Nueva York, con un valor de mercado agregado de $1.606.670,20 y una fecha aproximada de venta de 09/08/2025. Las acciones fueron adquiridas el 04/09/2025 mediante el ejercicio de Stock Appreciation Rights (2.782 y 1.054 acciones) y el pago se registr贸 como compensatorio.
El declarante indica que no se vendieron valores en los tres meses anteriores e incluye la declaraci贸n est谩ndar de que el vendedor no tiene conocimiento de informaci贸n material adversa no divulgada. Varios campos identificativos del declarante y del emisor (CIK, nombres, direcciones) no est谩n rellenados en el contenido proporcionado.
HCA Healthcare, Inc. (HCA)電� Merrill Lynch毳� 韱淀暣 雺挫殨歃濌秾瓯半灅靻岇棎靹� 齑� 鞁滌灔臧�旃� $1,606,670.20鞐� 頃措嫻頃橂姅 3,836 氤错喌欤� 毵り皝 鞝滌晥鞚� 瓿奠嫓頄堨溂氅�, 鞓堨爼 毵り皝鞚检潃 2025-09-08搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 2025-09-04鞐� Stock Appreciation Rights(臧侁皝 2,782欤� 氚� 1,054欤�) 頄夓偓搿� 旆摑霅橃棃瓿�, 雽�旮堨潃 氤挫儊靹�(肠辞尘辫别苍蝉补迟辞谤测)鞙茧 旮半霅橃棃鞀惦媹雼�.
鞁犼碃鞚胳潃 歆�雮� 3臧滌洈臧� 毵る弰頃� 鞙犼皜歃濌秾鞚� 鞐嗢潓鞚� 氤搓碃頃橂┌, 毵る弰鞚胳澊 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒鞐� 雽�頃� 鞎岇 氇豁暅雼る姅 響滌 歆勳垹鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖霅� 雮挫毄鞐愳劀電� 鞁犼碃鞚� 氚� 氚滍枆鞚胳潣 鞐煬 鞁濍硠 頃勲摐(CIK, 鞚措, 欤检唽 霌�)臧� 牍勳柎 鞛堨姷雼堧嫟.
HCA Healthcare, Inc. (HCA) r茅v猫le une proposition de vente de 3 836 actions ordinaires via Merrill Lynch 脿 la Bourse de New York, pour une valeur de march茅 globale de 1 606 670,20 $ et une date de vente approximative au 08/09/2025. Les actions ont 茅t茅 acquises le 04/09/2025 par l鈥檈xercice de Stock Appreciation Rights (2 782 et 1 054 actions) et le paiement a 茅t茅 enregistr茅 comme compensatoire.
Le d茅clarant indique qu鈥檃ucun titre n鈥檃 茅t茅 vendu au cours des trois mois pr茅c茅dents et inclut la d茅claration standard selon laquelle le vendeur n鈥檃 connaissance d鈥檃ucune information d茅favorable mat茅rielle non divulgu茅e. Plusieurs champs d鈥檌dentification du d茅clarant et de l鈥櫭﹎etteur (CIK, noms, adresses) ne sont pas renseign茅s dans le contenu fourni.
HCA Healthcare, Inc. (HCA) gibt eine vorgeschlagene Ver盲u脽erung von 3.836 Stammaktien 眉ber Merrill Lynch an der New York Stock Exchange mit einem Gesamtmarktwert von $1.606.670,20 und einem ungef盲hren Verkaufsdatum 08.09.2025 an. Die Aktien wurden am 04.09.2025 durch Aus眉bung von Stock Appreciation Rights (2.782 und 1.054 Aktien) erworben und die Zahlung wurde als compensatory erfasst.
Der Melder berichtet, dass in den vorangegangenen drei Monaten keine Wertpapiere verkauft wurden, und enth盲lt die standardm盲脽ige Erkl盲rung, dass dem Verk盲ufer keine nicht offengelegten wesentlichen nachteiligen Informationen bekannt sind. Mehrere Identifikationsfelder des Melders und des Emittenten (CIK, Namen, Adressen) sind in den bereitgestellten Inhalten nicht ausgef眉llt.
- Securities were acquired via compensatory Stock Appreciation Right exercises, indicating the transaction arises from standard employee/executive compensation
- Broker and exchange are specified (Merrill Lynch; New York), and an approximate sale date is provided (09/08/2025)
- Filer and issuer identification fields are not populated in the provided content, reducing transparency about who is selling
- Timing: rapid sale after SAR exercise (four days) could warrant attention but no further context is provided
Insights
TL;DR: Insider exercised SARs and plans a modest sale of 3,836 HCA shares valued at ~$1.6M; disclosure appears routine.
The filing documents a compensatory exercise of Stock Appreciation Rights followed by a proposed brokered sale four days later. This is a common liquidity event for executives or employees receiving equity-based pay. The transaction size (~3,836 shares, $1.61M) is material at the individual level but, without issuer outstanding share context beyond the provided 233,993,500 shares outstanding, it represents roughly 0.0016% of outstanding shares, a de minimis amount for market capitalization impact. Absence of filer identity fields reduces transparency for investor assessment.
TL;DR: Disclosure shows compensatory SAR exercise and planned sale; key filer identifiers are missing, limiting governance transparency.
The form properly states acquisition dates, nature (exercise of SARs), and that payment was compensatory, which aligns with executive compensation practices. The seller鈥檚 attestation about material nonpublic information is included. However, critical filer/issuer identification fields (names/CIK/contact details) are blank in the provided content, hindering stakeholders from linking this sale to a specific insider and assessing potential governance or signaling implications.
HCA Healthcare, Inc. (HCA) dichiara una proposta di vendita di 3.836 azioni ordinarie tramite Merrill Lynch alla New York Stock Exchange, per un valore complessivo di mercato di $1.606.670,20 e con data di vendita approssimativa 09/08/2025. Le azioni sono state acquisite il 04/09/2025 tramite l鈥檈sercizio di Stock Appreciation Rights (2.782 e 1.054 azioni) e il pagamento 猫 stato classificato come compensativo.
Il dichiarante segnala che non sono stati venduti titoli nei precedenti tre mesi e include la dichiarazione standard che il venditore non 猫 a conoscenza di informazioni riservate rilevanti non divulgate. Diversi campi identificativi del dichiarante e dell鈥檈mittente (CIK, nomi, indirizzi) non risultano compilati nel contenuto fornito.
HCA Healthcare, Inc. (HCA) informa sobre una propuesta de venta de 3.836 acciones ordinarias a trav茅s de Merrill Lynch en la Bolsa de Nueva York, con un valor de mercado agregado de $1.606.670,20 y una fecha aproximada de venta de 09/08/2025. Las acciones fueron adquiridas el 04/09/2025 mediante el ejercicio de Stock Appreciation Rights (2.782 y 1.054 acciones) y el pago se registr贸 como compensatorio.
El declarante indica que no se vendieron valores en los tres meses anteriores e incluye la declaraci贸n est谩ndar de que el vendedor no tiene conocimiento de informaci贸n material adversa no divulgada. Varios campos identificativos del declarante y del emisor (CIK, nombres, direcciones) no est谩n rellenados en el contenido proporcionado.
HCA Healthcare, Inc. (HCA)電� Merrill Lynch毳� 韱淀暣 雺挫殨歃濌秾瓯半灅靻岇棎靹� 齑� 鞁滌灔臧�旃� $1,606,670.20鞐� 頃措嫻頃橂姅 3,836 氤错喌欤� 毵り皝 鞝滌晥鞚� 瓿奠嫓頄堨溂氅�, 鞓堨爼 毵り皝鞚检潃 2025-09-08搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 2025-09-04鞐� Stock Appreciation Rights(臧侁皝 2,782欤� 氚� 1,054欤�) 頄夓偓搿� 旆摑霅橃棃瓿�, 雽�旮堨潃 氤挫儊靹�(肠辞尘辫别苍蝉补迟辞谤测)鞙茧 旮半霅橃棃鞀惦媹雼�.
鞁犼碃鞚胳潃 歆�雮� 3臧滌洈臧� 毵る弰頃� 鞙犼皜歃濌秾鞚� 鞐嗢潓鞚� 氤搓碃頃橂┌, 毵る弰鞚胳澊 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒鞐� 雽�頃� 鞎岇 氇豁暅雼る姅 響滌 歆勳垹鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖霅� 雮挫毄鞐愳劀電� 鞁犼碃鞚� 氚� 氚滍枆鞚胳潣 鞐煬 鞁濍硠 頃勲摐(CIK, 鞚措, 欤检唽 霌�)臧� 牍勳柎 鞛堨姷雼堧嫟.
HCA Healthcare, Inc. (HCA) r茅v猫le une proposition de vente de 3 836 actions ordinaires via Merrill Lynch 脿 la Bourse de New York, pour une valeur de march茅 globale de 1 606 670,20 $ et une date de vente approximative au 08/09/2025. Les actions ont 茅t茅 acquises le 04/09/2025 par l鈥檈xercice de Stock Appreciation Rights (2 782 et 1 054 actions) et le paiement a 茅t茅 enregistr茅 comme compensatoire.
Le d茅clarant indique qu鈥檃ucun titre n鈥檃 茅t茅 vendu au cours des trois mois pr茅c茅dents et inclut la d茅claration standard selon laquelle le vendeur n鈥檃 connaissance d鈥檃ucune information d茅favorable mat茅rielle non divulgu茅e. Plusieurs champs d鈥檌dentification du d茅clarant et de l鈥櫭﹎etteur (CIK, noms, adresses) ne sont pas renseign茅s dans le contenu fourni.
HCA Healthcare, Inc. (HCA) gibt eine vorgeschlagene Ver盲u脽erung von 3.836 Stammaktien 眉ber Merrill Lynch an der New York Stock Exchange mit einem Gesamtmarktwert von $1.606.670,20 und einem ungef盲hren Verkaufsdatum 08.09.2025 an. Die Aktien wurden am 04.09.2025 durch Aus眉bung von Stock Appreciation Rights (2.782 und 1.054 Aktien) erworben und die Zahlung wurde als compensatory erfasst.
Der Melder berichtet, dass in den vorangegangenen drei Monaten keine Wertpapiere verkauft wurden, und enth盲lt die standardm盲脽ige Erkl盲rung, dass dem Verk盲ufer keine nicht offengelegten wesentlichen nachteiligen Informationen bekannt sind. Mehrere Identifikationsfelder des Melders und des Emittenten (CIK, Namen, Adressen) sind in den bereitgestellten Inhalten nicht ausgef眉llt.
FAQ
What is being sold in the HCA (HCA) Form 144 filing?
When were the HCA shares acquired and how?
Which broker and exchange are involved in the proposed sale?
Is there any record of prior sales by the seller in the past three months?
Does the filing disclose any material nonpublic information or 10b5-1 plan date?
